The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aim. To compare the effects of once-weekly Dulaglutide with once-daily glargine in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus (T2DM). Method. A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group (n=16) and glargine group (n=9). All patients received either Dulaglutide or glargine treatments for 52 weeks. Continuous glucose monitoring systems (CGMS) were applied to them for two 72 h periods at before and after the treatment each. Patient general clinical data were collected and analyzed. Result. Fast blood glucose (FBG) of the glargine group declined more significantly than the Dulaglutide group after treatment (p<0.05). The mean blood glucose (MBG), standard deviation of blood glucose (SDBG), mean amplitude of glycemic excursion (MAGE) within a day, the largest amplitude of glycemic excursion (LAGE), M-value, absolute means of daily difference (MODD) of glycemic excursion, the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9–7.8 mmol/L, and 9–10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (p>0.05). The incidence of hypoglycemia was also similar between the two groups (p>0.05). Though serum levels of TNF-α, IL-6, and 8-PGF2 α all decreased, significant reduction was found in TNF-α and 8-PGF2 α. TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2 α was seen in both groups. Conclusion. For T2DM patients with poorly controlled oral antidiabetic drugs, once-weekly Dulaglutide not only has the same effect on glucose fluctuation as once-daily glargine but also significantly reduced TNF-α and 8-PGF2 α after a 52 week treatment protocol. This trial is registered with ClinicalTrials.gov NCT01648582.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Dulaglutide activates GLP-1 receptors, improves glucose-dependent insulin secretion, lowers patient’s fasting blood glucose, suppresses the postprandial secretion of glucagon, reduces postprandial glucose, prolongs gastric emptying time, decreases appetite, and improves pancreatic β-cell functioning [7].”
BackgroundWysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284 · cited 1×
“is is consistent with AWARD-3 and -5 studies, which did not nd dierence in occurrence of hypoglycemia in Dulaglutide injection and oral-drug taking groups [16, 17].”
ResultGiorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268 · cited 2×
“Similarly, AWARD-2 trial [18] found that on week 52, the total rate and the total times of hypoglycemia and nocturnal hypoglycemia of the glargine group were all higher than those of Dulaglutide groups.”
BackgroundResultThe FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Service, F. J., & O'Brien, P. C. (2001) · Diabetologia · doi:10.1007/s001250100635 · Cited by 106 · cited 2×
“Recently, glucose ¦uctuation has been a new indicator in evaluating blood glucose [8].”
BackgroundNauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Research works printed but not linked: 16
- 10.1016/j.diabres.2017.03.024 · DOI · Paper page
- 10.1016/j.arcmed.2005.01.003 · DOI · Paper page
- 2011, Pharmaceutical Journal, 1
- 10.1053/j.gastro.2007.03.054 · DOI · Paper page
- 10.1002/dmrr.1080 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01365.x · DOI · Paper page
- 10.1016/j.diabres.2007.08.007 · DOI
- 10.1016/S0140-6736(15)60936-9 · DOI · Paper page
- 10.1111/dom.12705 · DOI · Paper page
- 10.2337/db12-1610 · DOI · Paper page
- 10.2337/dc16-1738 · DOI · Paper page
- 10.2337/dc13-2759 · DOI · Paper page
- 10.1111/dom.12540 · DOI · Paper page
- 10.2337/dc14-0001 · DOI · Paper page
- 10.2337/dc14-0876 · DOI · Paper page
- 10.1007/s00125-009-1556-8 · DOI · Paper page
Cited by
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Zhao, F., Wang, H., Li, S., Yun, H., & Su, W. (2026) · PeerJ · doi:10.7717/peerj.20710 · Cited by 6
“…et al. (2022) ; Yan et al. (2019) ; The FLAT-SUGAR Trial Investigators (2016) ; Bunck et al. (2010) ; Derosa et al. (2010) ; Forst et al. (2012) ; Li et al. (2019) ; Lin et al. (2015) ; Pastel et al. (2017) ; Quan et al. (2017) ; Shao et al. (2024) ; Shi et al. (2017) ; Wu et al. (2011) ; Gurkan…”
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Metadata
- Authors
- Wang, J., Li, H.-Q., Xu, X.-H., Kong, X.-C., Sun, R., Jing, T., Ye, L., Su, X.-F., & Ma, J.-H.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2019-12-25
- Volume
- 2019
- Pages
- 1-8
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2997768671
- Cited by
- 23
- References
- 8
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Government of Jiangsu Province (BL2014010)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1155/2019/2682657
- The paper
- Wang, J., Li, H.-Q., Xu, X.-H., Kong, X.-C., Sun, R., Jing, T., Ye, L., Su, X.-F., & Ma, J.-H. (2019). The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus. BioMed Research International. https://doi.org/10.1155/2019/2682657
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.